Citations

Clear

941 citation(s) found for "Tan, MH".

Abstract LB-210: Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Roemeling, Christina A. von, Wu, Kevin J. , Tan, Winston , Copland, John A. , Mathias, Adam , Harrison, Chuck, Dawson, Louis K., Hollister, Beth, Roemeling, Christina A. Von , Marlow, Laura A. , Caulfield, Thomas R. , Tun, Han W.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: LB-210-LB-210

10.1158/1538-7445.am2013-lb-210 Get It

Abstract Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC, which is the most prevalent kidney cancer among adults. Of the patients who develop this disease, over 1/3 will already present with advanced or metastatic disease during initial diagnosis due to the lack of symptoms in early stages. RCC demonstrates considerable resistance to radiation and traditional chemotherapeutics. Despite advances in the development of targeted anti-cancer treatments, no current drug therapy leads to significant improvement in long term survival in patients with advanced disease with the rare exception of those who respond to immunotherapy. Additionally, patients inevitably develop drug resistance. Therefore new molecular targets for therapy are sorely needed. Our group has identified stearoyl coA desaturase (SCD1) as a novel molecular target in ccRCC. We examined its role in tumor cell growth and viability in vitro and in vivo independently as well as in combination with current FDA approved regimens. Methods: Patient normal and ccRCC tissue samples and cell lines were examined for SCD1 expression. Genetic knockdown models and targeted inhibition of SCD1 through use of a small molecule inhibitor were analyzed for growth, apoptosis, and alterations in gene expression using gene array analysis. Therapeutic models of synergy were evaluated utilizing pharmacologic inhibition of SCD1 with the tyrosine kinase inhibitors (TKI) sunitinib and pazopanib, and the mTOR inhibitor temsirolimus. Results: Our studies identify increased SCD1 expression in all stages of ccRCC. Both genetic knockdown and pharmacologic inhibition of SCD1 decrease tumor cell proliferation and induce apoptosis in vitro and in vivo. Upon gene array, quantitative real-time PCR, and protein analysis of SCDi treated or SCD1 lentiviral knockdown samples, induction of endoplasmic reticulum (ER) stress response signaling was observed, providing mechanistic insight for SCD1 activity in ccRCC. Furthermore, combinatorial application of SCDi with temsirolimus synergistically inhibits tumor growth in vitro and in vivo. Conclusions: Increased SCD1 expression supports ccRCC viability and therefore we propose it as a novel molecular target for therapy either independently or in combination with an mTOR inhibitor for patients whose disease cannot be remedied with surgical intervention, such as in cases of advanced or metastatic disease. These findings support the further evaluation of targeting SCD1 as an anti-cancer strategy in a phase I clinical trial. Citation Format: Christina A. von Roemeling, Laura Marlow, Thomas Caulfield, Kevin Wu, Winston Tan, Han Tun, John A. Copland, Adam Mathias, Chuck Harrison, Louis Dawson, Beth Hollister. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-210. doi:10.1158/1538-7445.AM2013-LB-210
Abstract B273: Multicenter Phase II study of MK-2206 in previously treated patients (pts) with recurrent and metastatic nasopharyngeal carcinoma (NPC): Mayo Clinic Phase II Consortium (Protocol: MC1079).
Ma, Brigette , Lim, Wan Teck, Tan, Eng Huat, Lopes, Gilberto , King, Ann D. , Loong, Herbert H. , Foster, Nathan R. , Kam, Michael , Leung, Sing Fai, Erlichman, Charles , Chan, Anthony T.�C. , Goh, Boon Cher , Lim, Wan Teck, Hui, Edwin Pun , Lo, Kwok Wai , Li, Leung , Loong, Herbert H , Ma, Brigette B Y

Mayo Clinic

Molecular Cancer Therapeutics | August 14, 2014 | Volume: 12 | Issue: 11_Supplement | Pages: B273-B273

10.1158/1535-7163.targ-13-b273 Get It

Abstract Background: NPC is endemic to Asia and over 40% of cases harbor PIK3CA amplification. MK2206 is an allosteric AKT inhibitor with activity in NPC in vitro. Methods: Pts who had progressed after palliative chemotherapy (chemo) for metastatic or recurrent NPC, received oral MK-2206 at 200 mg on Days 1, 8, 15 & 22 of each 28-day cycle until disease progression. Plasma samples were collected at serial time points during cycle 1 for EBV DNA analysis, archived tumor samples were collected where feasible. The primary dual endpoints (2-stage design) consisted of RECIST-defined tumor response rate (RR) and 6-month (m) progression-free survival (PFS) rate. Secondary endpoints were overall survival (OS), PFS and adverse events (AEs). Results: Of the 21 pts enrolled, the median age was 47 years (range: 32-67), 91% were male, 81% had prior radiotherapy and 81% had > 1 prior line of palliative chemo. At the time of analysis, 20 out of 21 pts have ended treatment. The best responses were: 1 partial response (PR, 5%) lasting 4 ms; 10 stable disease (SD, 50%), 9 progressive disease (PD, 45%). The 6-m PFS rate was 38.9% (95% CI: 18.1-59.3%) and median PFS was 2.7 ms (95% CI: 0.9-7.2 ms). The 6-m OS rate was 67.9% (95% CI: 41.8-84.1%) and median survival has not been reached. In 7 pts who had SD more than or equal to 6 ms, the duration of treatment ranged from 6.4-13.9 ms. Of the 21 pts evaluable for AEs, 12 pts (57%) had at least one grade 3 AE [[Unable to Display Character: –]] macular rash (6 pts - 29%), dysphagia (2 pts - 10%), hyperglycemia (2 pts - 10%) (see Table 1). The tumor samples of 7 pts were analyzed by FISH; 3 showed PIK3CA amplification, including 1 pt with chromosome 3 polysomy. Amongst these pts, 1 had SD more than 6ms, 1 had SD more than 12 ms, and 1 is still on treatment. Pts who had SD less than 6 m or PD did not have PIK3CA amplification. Conclusions: MK2206 is well tolerated and has signs of activity in unselected pts with NPC. Preliminary results suggest that PIK3CA amplification may be related to prolonged disease stabilization from MK2206, and analysis for other PIK3CA gene alterations in more samples will be undertaken. Result of the plasma EBV DNA result will be presented. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B273. Citation Format: Brigette B. Ma, Boon Cher Goh, Wan Teck Lim, Eng Huat Tan, Gilberto de Lima Lopes, Edwin P. Hui, Ann D. King, Kwok Wai Lo, Herbert Loong, Leung Li, Nathan Foster, Michael Kam, Sing Fai Leung, Charles Erlichman, Anthony TC Chan. Multicenter Phase II study of MK-2206 in previously treated patients (pts) with recurrent and metastatic nasopharyngeal carcinoma (NPC): Mayo Clinic Phase II Consortium (Protocol: MC1079). [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B273.
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer
Landreneau, Rodney J., Mandrekar, Sumithra J. , Nichols, Francis C., Hillman, Shauna L., Heron, Dwight E. , Meyers, Bryan F., DiPetrillo, Thomas A., Jones, David R. , Tan, Angelina D., Daly, Benedict D.T., Putnam, Joe B. , Fernando, Hiran C. , Starnes, Sandra L, Meyers, Bryan F. , Starnes, Sandra Lynne , Jones, David R

Mayo Clinic

Journal of Clinical Oncology | July 1, 2014 | Volume: 32 | Issue: 23 | Pages: 2456-2462

10.1200/jco.2013.53.4115 | PMID 24982457 Get It

Purpose A major concern with sublobar resection (SR) for non–small-cell lung cancer (NSCLC) is high local recurrence (LR). Adjuvant brachytherapy may reduce LR This multicenter randomized trial compares SR to SR with brachytherapy (SRB). Patients and Methods High-risk operable patients with NSCLC ≤ 3 cm were randomly assigned to SR or SRB. The primary end point was time to LR, where LR included recurrence at the staple line (local progression), in the primary tumor lobe away from the staple line, and in ipsilateral hilar nodes. The trial was designed to have a 90% power to detect a hazard ratio (HR) of 0.315 in favor of SRB, using a one-sided type I error rate of 0.05 with a sample size of 100 eligible patients in each arm. Results Two hundred twenty-four patients were randomly assigned; 222 patients were evaluable for intent-to-treat analysis. Median age was 71 years (range, 49 to 87 years). No differences were found in baseline characteristics. Median follow-up time was 4.38 years (range, 0.04 to 5.59 years). There was no difference in time to LR (HR, 1.01; 95% CI, 0.51 to 1.98; log-rank P = .98) or in the types of LR. Local progression occurred in only 17 (7.7%) of 222 patients. In patients with potentially compromised margins (margin < 1 cm, margin-to-tumor ratio < 1, positive staple line cytology, wedge resection, nodule size > 2.0 cm), SRB did not reduce LR, although trends favored the SRB arm. This was most marked in 14 patients with positive staple line cytology (HR, 0.22; P = .24). Three-year overall survival rates were similar for patients in the SR (71%) and SRB (71%) arms (P = .97). Conclusion Brachytherapy did not reduce LR after SR. This finding may have been related to closer attention to parenchymal margins by surgeons participating in this study.
Desulfovibrio legallii Prosthetic Shoulder Joint Infection and Review of Antimicrobial Susceptibility and Clinical Characteristics of Desulfovibrio Infections
Vasoo, Shawn , Mason, Erin L., Gustafson, Daniel R., Cunningham, Scott A. , Cole, Nicolynn C., Vetter, Emily A., Steinmann, Scott P. , Wilson, Walter R., Patel, Robin , Berbari, Elie F. , Henry, Nancy K., Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | May 22, 2014 | Volume: 52 | Issue: 8 | Pages: 3105-3110

10.1128/jcm.00083-14 | PMID 24850351 Get It

ABSTRACT We describe a case of shoulder hemiarthroplasty infection with Desulfovibrio legallii . Antimicrobial susceptibilities of 36 Desulfovibrio isolates are presented. Metronidazole and carbapenems exhibited reliable activity, although piperacillin-tazobactam did not. Eleven previous cases of Desulfovibrio infection are reviewed; most arose from a gastrointestinal tract-related source.
Mycobacterium arupense Flexor Tenosynovitis: Case Report and Review of Antimicrobial Susceptibility Profiles for 40 Clinical Isolates
Beam, Elena , Vasoo, Shawn , Simner, Patricia J. , Rizzo, Marco , Mason, Erin L., Walker, Randall C., Deml, Sharon M., Brown‐Elliott, Barbara A. , Wallace, Richard J. , Wengenack, Nancy L. , Sia, Irene G. , Beam, Elena , Sia, Irene G

Mayo Clinic

Journal of Clinical Microbiology | May 1, 2014 | Volume: 52 | Issue: 7 | Pages: 2706-2708

10.1128/jcm.00277-14 | PMID 24789193 Get It

ABSTRACT We describe a case of chronic tenosynovitis in the hand of a 58-year-old cattle farmer. Surgical biopsy specimens grew Mycobacterium arupense . The patient responded to surgery and antimicrobial therapy based on in vitro susceptibility testing. The antimicrobial susceptibility profiles of the isolate from this patient and 39 additional clinical isolates are presented.
Human Finger-Prick Induced Pluripotent Stem Cells Facilitate the Development of Stem Cell Banking
Tan, Hong-Kee, Toh, Cheng-Xu Delon, Ma, Dongrui , Yang, Binxia , Liu, Tongming , Lu, Jun , Wong, Chee-Wai , Tan, Tze-Kai , Syn, Christopher Kiu‐Choong , Tan, Eng-Lee, Lim, Bing , Lim, Yoon-Pin, Loh, Yuin‐Han , Li, Hu , Lim, Yoon-Pin, Cook, Stuart A. , Loh, Yuin-Han

Mayo Clinic

Stem Cells Translational Medicine | March 20, 2014 | Volume: 3 | Issue: 5 | Pages: 586-598

10.5966/sctm.2013-0195 | PMID 24646489 Get It

Abstract Induced pluripotent stem cells (iPSCs) derived from somatic cells of patients can be a good model for studying human diseases and for future therapeutic regenerative medicine. Current initiatives to establish human iPSC (hiPSC) banking face challenges in recruiting large numbers of donors with diverse diseased, genetic, and phenotypic representations. In this study, we describe the efficient derivation of transgene-free hiPSCs from human finger-prick blood. Finger-prick sample collection can be performed on a “do-it-yourself” basis by donors and sent to the hiPSC facility for reprogramming. We show that single-drop volumes of finger-prick samples are sufficient for performing cellular reprogramming, DNA sequencing, and blood serotyping in parallel. Our novel strategy has the potential to facilitate the development of large-scale hiPSC banking worldwide.
Alpha‐synuclein repeat variants and survival in Parkinson's disease
Armasu, Sebastian M. , Anderson, Kari, Frigerio, Roberta , Aasly, Jan , Annesi, Grazia , Bentivoglio, Anna Rita , Brighina, Laura , Chartier‐Harlin, Marie‐Christine , Goldwurm, Stefano , Jasińska‐Myga, Barbara, Jeon, Beom Seok , Kim, Yun Joong , Krüger, Rejko , Lesage, Suzanne , Markopoulou, Katerina , Mellick, George D. , Morrison, Karen , Puschmann, Andreas , Tan, Eng‐King , Crosiers, David , Broeckhoven, Christine Van , Wirdefeldt, Karin , Maraganore, Demetrius M. , Chung, Sun Ju , Biernacka, Joanna M. , Hadjigeorgiou, Georgios M. , Theuns, Jessie , Wszołek, Zbigniew K. , Elbaz, Alexis , Puschmann, Andreas

Mayo Clinic

Movement Disorders | February 27, 2014 | Volume: 29 | Issue: 8 | Pages: 1053-1057

10.1002/mds.25841 | PMID 24578302 Get It

ABSTRACT Objectives To determine whether α‐synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium provided REP1 genotypes and baseline and follow‐up clinical data for cases. The primary outcome was time to death. Cox proportional hazards regression models were used to assess the association of REP1 genotypes with survival. Results Twenty‐one sites contributed data for 6,154 cases. There was no significant association between α‐synuclein REP1 genotypes and survival in PD. However, there was a significant association between REP1 genotypes and age at onset of PD (hazard ratio: 1.06; 95% confidence interval: 1.01‐1.10; P value = 0.01). Conclusions In our large consortium study, α‐synuclein REP1 genotypes were not associated with survival in PD. Further studies of α‐synuclein's role in disease progression and long‐term outcomes are needed. © 2014 International Parkinson and Movement Disorder Society
Campylobacter Prosthetic Joint Infection
Vasoo, Shawn , Schwab, Jeramy J., Cunningham, Scott A. , Robinson, Trisha J., Cass, Joseph R., Berbari, Elie F. , Walker, Randall C., Osmon, Douglas R. , Patel, Robin , Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | February 13, 2014 | Volume: 52 | Issue: 5 | Pages: 1771-1774

10.1128/jcm.03572-13 | PMID 24523462 Get It

ABSTRACTA 75-year-old man was diagnosed with probableCampylobacter jejuniprosthetic knee infection after a diarrheal illness. Joint aspirate and operative cultures were negative, but PCR of prosthesis sonicate fluid was positive, as was stool culture. Nineteen additional cases ofCampylobacterprosthetic joint infection reported in the literature are reviewed.
Prevalence of Primary Aldosteronism among Asian Hypertensive Patients in Singapore1
Loh, Keh‐Chuan, Koay, Evelyn S. C., Khaw, Min-Cheh, Emmanuel, Shanta, Khaw, Min-Cheh, Young, William F.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 8, 2014 | Volume: 85 | Issue: 8 | Pages: 2854-2859

10.1210/jcem.85.8.6752 | PMID 10946893 Get It

Integrative Gene Set Analysis: Application to Platinum Pharmacogenomics
Abo, Ryan, Tan, Xiang-Lin, Jenkins, Gregory D. , Batzler, Anthony , Moyer, Ann M. , Wang, Liewei , Fridley, Brooke L. , Tan, Xiang‐Lin, Biernacka, Joanna M.

Mayo Clinic

OMICS: A Journal of Integrative Biology | November 7, 2013 | Volume: 18 | Issue: 1 | Pages: 34-41

10.1089/omi.2013.0099 | PMID 24199607 Get It

Abstract Integrative genomics has the potential to uncover relevant loci, as clinical outcome and response to chemotherapies are most likely not due to a single gene (or data type) but rather a complex relationship involving genetic variation, mRNA, DNA methylation, and copy number variation. In addition to this complexity, many complex phenotypes are thought to be controlled by the interplay of multiple genes within the same molecular pathway or gene set (GS). To address these two challenges, we propose an integrative gene set analysis approach and apply this strategy to a cisplatin (CDDP) pharmacogenomics study involving lymphoblastoid cell lines for which genome-wide SNP and mRNA expression data was collected. Application of the integrative GS analysis implicated the role of the RNA binding and cytoskeletal part GSs. The genes LMNB1 and CENPF, within the cytoskeletal part GS, were functionally validated with siRNA knockdown experiments, where the knockdown of LMNB1 and CENPF resulted in CDDP resistance in multiple cancer cell lines. This study demonstrates the utility of an integrative GS analysis strategy for detecting novel genes associated with response to cancer therapies, moving closer to tailored therapy decisions for cancer patients.